A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
Mai Suzuki(Japanese Foundation For Cancer Research), Ryohei Katayama(Japanese Foundation For Cancer Research)
Cited by 11
Related Papers
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
|Nature Communications|2017|409
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
|EBioMedicine|2015|140
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
|EBioMedicine|2019|125
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
|Nature Communications|2021|100